Robert Lustig: The Invisible Danger of Fatty Liver Requires Biomarker Assessment
Short excerpt from a YouTube talk (Robert Lustig, presented/uploaded by Dr. Ron Najafi) arguing that hidden/internal fat (not visible adiposity) is the medically relevant problem. The speaker contrasts visible versus invisible fat, highlights nonalcoholic fatty liver disease (NAFLD) as an example of hidden fat, and states a specific epidemiologic claim: adolescents in America with NAFLD have a 2.6% increased risk of developing type 2 diabetes.
Questions this video answers
2.6% increased risk
Chapters
More from Dr.
Hippocrates said, let thy food be thy medicine #obesity #metabolicsyndrome #lustig #shorts #health
Bill Wilson, MD: Why GLP-1 Drugs Are Overpriced—and How Compounding and Competition Could Fix It
Nitrosamine in Pharmaceutical Products? A Deep Dive into Risk Management by Ron Najafi, Ph.D.
The Subcellular Processes That Belie All Chronic Disease. The Hateful (or Grateful) Eight #lustig
Bill Wilson, MD: GLPs May Reverse Carb Syndrome—Helping Patients Reach Zero and Sustain with Diet
Why Everything You Knew About Obesity Is Wrong | Dr. Robert Lustig on Sugar & Metabolic Syndrome
Robert Lustig, MD: How Fructose Fuels Fatty Liver, Oxidative Stress, and Metabolic Disease #fructose
Robert Lustig, MD: The 3 Types of Fat Fueling Insulin Resistance and Disease #insulin resistance
Bill Wilson, MD: GLPs May Reverse CARB Syndrome. Helping Patients Reach Zero and Sustain with Diet